ATYR: aTyr Pharma Inc Price to Sales
The P/S ratio history demonstrates the market transparency of aTyr Pharma, Inc. (ATYR), with the 78.50 mark reflecting the latest data. aTyr Pharma, Inc. (ATYR) focuses on developing protein immunotherapy for rare lung pathologies, leveraging its patent portfolio. However, geopolitical tensions and logistical complexities could hinder the procurement of ingredients. High demand in specialized centers provides potential for the commercialization of new drugs.
Metric breakdowns and analytics for aTyr (ATYR)
- stock price and consensus target price:
- market capitalization information:
- shareholders' equity book value data:
- debt obligations and liquidity statistics:
- company profitability and valuation multiples indicators:
ATYR - Net Profit|Projected Future Earnings aTyr Pharma, Inc.|ATYR - Price to Earnings Ratio|Future Price to Earnings Multiple aTyr Pharma Inc|ATYR - Price/Earnings to Growth Ratio|Enterprise Value to EBITDA Ratio aTyr|ATYR - Operating profit EBITDA|Net earnings per share (EPS TTM) aTyr Pharma|ATYR - Net earnings per share for the last 12 months|Year-over-year earnings per one share growth for the last 12 months atyrpharma.com|ATYR - Earnings growth in current year|Consensus forecast of earnings per share growth for next year aTyr Pharma, Inc.
- sales revenue and business income indicators:
Summary company analytics:atyrpharma.com, ATYR
An objective business valuation is critical for capital protection amid uncertainty. The P/S ratio compares market capitalization to annual sales volume, determining the premium the market is willing to pay per unit of revenue. By analyzing the current P/S level, an investor assesses the degree to which an asset is overbought. For aTyr Pharma, Inc. (ATYR), this metric reflects expectations regarding the lack of alternatives for fibrous disease therapies and long-term margin stability.
Competitors of aTyr Pharma, Inc.
argenx.com - Market Cap to Revenue Ratio|P/S Multiple BNTX (BioNTech)|Abivax Pharma (ABVX) - Price to Sales|ADMA Bio - P/S Multiple|PTGX - P/S Multiple|IMVT (Immunovant, Inc.) - Market Cap to Revenue|KNSA: Market Cap to Sales Volume|Market Cap to Revenue GRFS|Price to Sales Adaptive Biotech ADPT|Price-to-Revenue Ratio Celldex (CLDX)|AUPH (Aurinia Corp) - Market Capitalization-to-Revenue Ratio|BioCryst - Market Cap to Revenue|Market Capitalization-to-Revenue Ratio VERA|DNTH - Price-to-Revenue Ratio|Price-to-Sales Ratio PHVS|ABCL: P/S Multiple|Tourmaline - Market Capitalization-to-Revenue Ratio|PGEN (Precigen, Inc.) - P/S Multiple|P/S Multiple pharming.com|Price-to-Revenue Ratio Nektar Therapeutics Inc. (NKTR)|UPB (Upstream Bio, Inc.) - Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio Zenas Biopharma, Inc. ZBIO|IMNM - Market Cap to Revenue|Gossamer Bio, Inc. - P/S Multiple|KALV - P/S Multiple|SEPN (Septerna) - Market Cap to Revenue|Pieris Pharma - Market Capitalization-to-Revenue Ratio|SVRA (Savara Corp) - P/S Multiple|Rigel Corp (RIGL) - Price-to-Revenue Coefficient|Price-to-Revenue Ratio AnaptysBio, Inc. (ANAB)|astriatx.com - Market Cap to Revenue Ratio|P/S Multiple ENGN (enGene)|RAPT - Market Cap to Revenue|JBIO: Market Cap to Revenue|Price-to-Revenue Coefficient Aclaris Therapeutics, Inc ACRS|KYTX: P/S Multiple|tizianalifesciences.com (TLSA) - P/S Multiple|Market Cap to Revenue CABA|VTYX (Ventyx Biosciences Inc.) - Market Cap to Sales Volume|Market Cap to Revenue THTX (Theratechnologies Inc)|AVTX - Price to Sales|Price-to-Revenue Ratio Eledon Pharmaceuticals ELDN|Market Capitalization-to-Revenue Ratio AGEN|CLYM - Price-to-Revenue Ratio|Price-to-Sales Ratio ZURA|ADAG: P/S Multiple|Ikena Oncology - Market Capitalization-to-Revenue Ratio|STTK (Shattuck Labs Inc) - P/S Multiple|P/S Multiple Equillium Bio|Price-to-Revenue Ratio Connect Biopharma (CNTB)|IMUX (immunic-therapeutics.com) - Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio Atara Bio ATRA|IFRX - Market Cap to Revenue|X4 Pharmaceuticals - P/S Multiple|ACET - P/S Multiple|CELU (celularity.com) - Market Cap to Revenue|INmune Bio Inc - Market Capitalization-to-Revenue Ratio|BRNS (Barinthus Bio) - P/S Multiple|Kezar Life Sciences Inc (KZR) - Price-to-Revenue Coefficient|Price-to-Revenue Ratio SAB Biotherapeutics (SABS)|Market Cap to Revenue akaritx.com AKTX|Price-to-Revenue Ratio Enlivex Therapeutics Ltd. ENLV|QTTB - Market Cap to Revenue|GOVX: Market Cap to Revenue|EDSA - P/S Multiple|iBio, Inc. (IBIO) - Price-to-Revenue Ratio|Market Cap to Revenue Ratio CARM|XTLB (XTL Biopharmaceuticals Ltd.) - P/S Multiple|Price to Sales Bolt Bio BOLT|P/S Multiple HCWB|P/S Multiple aptevotherapeutics.com (APVO)|AIM ImmunoTech Inc. - Market Cap to Revenue|Market Cap to Sales Volume ADTX (Aditxt Inc.)|GRI: Market Cap to Revenue|Price to Sales XORTX Therapeutics Inc|ReShape Lifesciences (HIND) - Price-to-Revenue Ratio|Revelation Biosciences Corp - Market Capitalization-to-Revenue Ratio|Market Cap to Revenue INDP|SCNI: Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio CalciMedica, Inc. (CALI)|AFMD: Price-to-Sales Ratio|P/S Multiple ALLK (Allakos)|Market Capitalization-to-Revenue Ratio HOOK|IGM Bio - P/S Multiple|ITOS - P/S Multiple|Ocean Biomedical (OCEA) - Price-to-Revenue Ratio|TC BioPharm (Holdings) Plc - Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio Third Harmonic Bio, Inc
